KTH Royal Institute of Technology

Grindr Adds Three Key Executives On the Heels of Record Quarter Driven by Deeper User Engagement and New Subscription Options

Retrieved on: 
Tuesday, September 26, 2023
Legal, Mobile, Wireless, Technology, Marketing, LGBTQ+, Communications, Professional Services, Social Media, Consumer, Artificial Intelligence, Corporate Affairs, Federal Communications Commission, Yale College, Yale Law Journal, Travel, Equality, Piñeiro, General counsel, Munger, Tolles & Olson, LGBTQ, Culture, Yale Law School, KTH Royal Institute of Technology, White House Counsel, Communication, NYU, United States Court of Appeals for the Ninth Circuit, Age, Research, Federal, Princeton University, Royal institute, Government, Presidency of Barack Obama, Machine learning, Zeno, Artificial intelligence, Education minister, AI, UCLA, Grinder, Netflix, Native American policy of the Barack Obama administration, NYSE, Candy Crush Saga, Management, Grindr, Learning, Badoo, Varian

He was most recently Chief Legal & Corporate Affairs Officer at Age of Learning, a leading education technology company.

Key Points: 
  • He was most recently Chief Legal & Corporate Affairs Officer at Age of Learning, a leading education technology company.
  • Katz previously served in the Obama Administration, including as Chief of Staff and Chief Counsel of the Federal Communications Commission, and in the White House Counsel's Office.
  • He graduated from Yale Law School, where he was Editor-in-Chief of The Yale Law Journal, and from Yale College.
  • She is joining Grindr to lead the efforts in leveraging AI technology, which will be transformative to the dating industry, to improve user experience and expand AI-enabled features.

ChromaTan™ Appoints Dr. Rajiv Datar as New CEO

Retrieved on: 
Tuesday, September 19, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Food and Bioprocess Technology, Drug development, Massachusetts Institute of Technology, KTH Royal Institute of Technology, Exhibition, Bioprocess, Conference, Biochemical engineering, Fine chemical

ChromaTanTM announced today that Dr. Rajiv Datar has been appointed the new President & CEO of the company.

Key Points: 
  • ChromaTanTM announced today that Dr. Rajiv Datar has been appointed the new President & CEO of the company.
  • Recently, Dr. Datar was the Co-Founder & CEO of a biotech startup that developed an early-stage asset, which was acquired by a Global Top-5 Biopharma Company.
  • “It was immediately clear that Dr. Datar was the right fit,” said Steve Carpenter, Chair of the Board of Directors’ compensation committee.
  • “The board of ChromaTan is so pleased to have Dr. Datar join the company in this role.

Novatron Fusion Group closes seed round of EUR 5 million, accelerating the transformation to commercial fusion power

Retrieved on: 
Tuesday, August 29, 2023
FIA, Investment, General partnership, Research, The Crusaders (jazz fusion group), Fusion Industry Association, Plasma, EUR, EIT, Climate change, KTH Royal Institute of Technology, Physics, Knowledge, Lithium, 3D printing, Industrifonden

STOCKHOLM, Aug. 29, 2023 /PRNewswire/ -- The world's energy demand is growing rapidly, and we need to meet it without reliance on fossil fuels. Fusion power has the potential to provide a limitless supply of emissions-free, reliable, safe, and affordable energy for all. Fusion power would provide a much-needed solution to some of humanity's greatest challenges: the growing need for energy and accelerating climate change.

Key Points: 
  • Novatron Fusion Group, a Swedish company that aims to revolutionize the field of fusion energy production, announced today the successful closure of its seed round, raising EUR 5 million.
  • Fusion power would provide a much-needed solution to some of humanity's greatest challenges: the growing need for energy and accelerating climate change.
  • Peter Roos, CEO of Novatron Fusion Group, commented: "We are thrilled to receive such strong support from our investors.
  • Novatron Fusion Group is a member of the Fusion Cluster in the UK and the Fusion Industry Association (FIA) in the USA.

Novatron Fusion Group closes seed round of EUR 5 million, accelerating the transformation to commercial fusion power

Retrieved on: 
Tuesday, August 29, 2023
FIA, Investment, General partnership, Research, The Crusaders (jazz fusion group), Fusion Industry Association, Plasma, EUR, EIT, Climate change, KTH Royal Institute of Technology, Physics, Knowledge, Lithium, 3D printing, Industrifonden

STOCKHOLM, Aug. 29, 2023 /PRNewswire/ -- The world's energy demand is growing rapidly, and we need to meet it without reliance on fossil fuels. Fusion power has the potential to provide a limitless supply of emissions-free, reliable, safe, and affordable energy for all. Fusion power would provide a much-needed solution to some of humanity's greatest challenges: the growing need for energy and accelerating climate change.

Key Points: 
  • Novatron Fusion Group, a Swedish company that aims to revolutionize the field of fusion energy production, announced today the successful closure of its seed round, raising EUR 5 million.
  • Fusion power would provide a much-needed solution to some of humanity's greatest challenges: the growing need for energy and accelerating climate change.
  • Peter Roos, CEO of Novatron Fusion Group, commented: "We are thrilled to receive such strong support from our investors.
  • Novatron Fusion Group is a member of the Fusion Cluster in the UK and the Fusion Industry Association (FIA) in the USA.

Koneksa Appoints Dave Hurry as Chief Data Officer and Dr. Larsson Omberg as EVP of Data Science

Retrieved on: 
Tuesday, June 27, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, Clinical Trials, Computational biology, UK Data Service, Sage Bionetworks, Drug development, Data science, Clinical trial, Raymond Lister (computer science researcher), Systems biology, Biomarker, Doctor of Philosophy, Security agency, Invention, Digital health, Patent, Cancer systems biology, Machine learning, Engineering, KTH Royal Institute of Technology, Physics, Artificial intelligence, Knowledge, Growth, Merck, Digital, Biostatistics, Cornell University, Computer science, Management, Medical imaging, Takeda, University of Texas at Austin

Koneksa, the evidence-based digital biomarkers company, today announced the appointment of Dave Hurry as Chief Data Officer and Larsson Omberg, Ph.D., as Executive Vice President of Data Science.

Key Points: 
  • Koneksa, the evidence-based digital biomarkers company, today announced the appointment of Dave Hurry as Chief Data Officer and Larsson Omberg, Ph.D., as Executive Vice President of Data Science.
  • They will focus on applying data science to unlock valuable insights and knowledge from clinical trial data.
  • Dr. Robert Ellis, current Head of Data Science and Co-founder, Koneksa, will transition to Head of Biomarker Exploration.
  • Dr. Larsson Omberg's appointment brings a unique blend of data science, computational biology, research management, and clinical perspective to Koneksa.

Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, April 17, 2023
AACR, KTH Royal Institute of Technology, ADCC, Cancer, NK, Cell, Patient, Annual general meeting, Karolinska Institute, Poster, IND, CD30, FC, Vaccine, Affimer

The preclinical data demonstrate the ability of AFM13, Affimed’s CD16A/CD30-targeting innate cell engager (ICE®), to induce serial killing of tumor cells, while preserving CD16A shedding.

Key Points: 
  • The preclinical data demonstrate the ability of AFM13, Affimed’s CD16A/CD30-targeting innate cell engager (ICE®), to induce serial killing of tumor cells, while preserving CD16A shedding.
  • The poster, shown at the Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, shared results from a live-cell microchip screening with single cell resolution.
  • AFM13 increased NK killing efficiency of CD30-positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC).
  • “AFM13 increased NK cell-mediated serial killing of tumor cells, even when they express low levels of CD30,” said Prof. Björn Önfelt.

NVIDIA Hopper GPUs Expand Reach as Demand for AI Grows

Retrieved on: 
Tuesday, March 21, 2023
Cloud, Communication, Amazon Web Services, NovelAI, Internet, Telecommunications, Microsoft, GTC, EC2, Emad Mostaque, GIGABYTE, Atos, Supermicro, DGX, 3D, Applied Physics Laboratory, Research, OpenAI, Organization, Hewlett Packard Enterprise, Work, Machine learning, KTH Royal Institute of Technology, Drug discovery, Stable Diffusion, Hopper, LLM, Meta, System, Grand Teton, ChatGPT, Creativity, Amazon, Google Cloud, Engineering, Generative, CyberAgent, Mitsui, Education, FP8, EFA, Transformer, Amazon Elastic Compute Cloud, A100, Oracle Cloud, Cisco, City, Lambda, AI, OCI, Dell Technologies, AWS, GPU, Dairy, Cryptocurrency, Video game, Medical device, Copper, H100, Lenovo, Azure, NVIDIA

SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- GTC —NVIDIA and key partners today announced the availability of new products and services featuring the NVIDIA H100 Tensor Core GPU — the world’s most powerful GPU for AI — to address rapidly growing demand for generative AI training and inference.

Key Points: 
  • NVIDIA founder and CEO Jensen Huang announced during his GTC keynote today that NVIDIA DGX™ H100 AI supercomputers are in full production and will be coming soon to enterprises worldwide.
  • The NVIDIA DGX H100 features eight H100 GPUs connected with NVIDIA NVLink® high-speed interconnects and integrated NVIDIA Quantum InfiniBand and Spectrum™ Ethernet networking.
  • DGX H100 also features the complete NVIDIA AI software stack, enabling enterprises to seamlessly run and manage their AI workloads at scale.
  • This offering includes the latest version of NVIDIA AI Enterprise , announced separately today, as well as NVIDIA Base Command ™, the operating system of the DGX data center, which coordinates AI training and operations across the NVIDIA DGX platform to simplify and streamline AI development.

Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for C

Retrieved on: 
Tuesday, March 14, 2023
PTCL, KTH Royal Institute of Technology, Cancer, AACR, Antibody-dependent cellular cytotoxicity, Annual general meeting, Abstract, Cell, Antibody, ADCC, Patient, Karolinska Institute, Natural killer T cell, CD30, NK, Vaccine, Pharmaceutical industry

An oral presentation will show detailed results from the AFM13 REDIRECT study evaluating the treatment of patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL).

Key Points: 
  • An oral presentation will show detailed results from the AFM13 REDIRECT study evaluating the treatment of patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL).
  • In addition, a poster presentation will highlight results from the collaboration study with Prof. Björn Önfelt, further elucidating AFM13’s mechanism of action.
  • Antibody-Dependent Cellular Cytotoxicity (ADCC) is a powerful mechanism of Natural Killer (NK) cells to kill antibody-opsonized target cells.
  • However, ADCC mediated by conventional antibodies has its limitations in killing of tumor cells commonly being characterized by low tumor antigen expression.

Keysight Collaborates with KTH Royal Institute of Technology to Achieve Record Baud Rates

Retrieved on: 
Wednesday, March 8, 2023
Technology, 5G, Telecommunications, Software, Networks, Internet, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, Riga Technical University, KTH Royal Institute of Technology, PAM4, OFC, NYSE, Research, Hertz, Growth, KTH, Machine learning, Data-rate units, Keysight, PAM16, Artificial intelligence, RTU, Optical networking, Renewable energy, Computer data storage

The achievement will be presented at OFC 2023 , the largest global conference for optical communications and networking professionals.

Key Points: 
  • The achievement will be presented at OFC 2023 , the largest global conference for optical communications and networking professionals.
  • Applications for machine learning, artificial intelligence, 5G and the internet of things are driving demand for ever increasing bandwidth.
  • Dr. Oskars Ozoliņš, RISE Research Institutes of Sweden, KTH and RTU, said: “Data center interconnects require simple and efficient solutions to reduce complexity.
  • Collaborations like this help to address the next leap in the technology wave.”

EnginZyme Raises €21 Million in Series B to Accelerate the Commercialisation of Its Cell-Free Biomanufacturing Technology

Retrieved on: 
Monday, December 19, 2022
Professional Services, Sustainability, Technology, Other Manufacturing, Environment, Green Technology, Engineering, Chemicals, Plastics, Biotechnology, Finance, Other Technology, Health, Manufacturing, Climate change, Engineering, Carbon footprint, Biotechnology, Biology, Enzyme, Nature, SEB, Sofinnova, Biochemistry, Siam, Multimedia, Venture round, World Economic Forum, Chemical engineering, KTH Royal Institute of Technology, Chemical industry, Investment, Renewable energy, Financial services, Industrifonden

EnginZyme, a green tech company developing biomanufacturing processes for the sustainable manufacturing of everyday products, announced today that it had raised €21 million in a Series B financing round.

Key Points: 
  • EnginZyme, a green tech company developing biomanufacturing processes for the sustainable manufacturing of everyday products, announced today that it had raised €21 million in a Series B financing round.
  • Its technology platform utilises nature’s catalysts, enzymes, combining the power of biology with the efficiency of the chemical industry in a best-of-both-worlds solution.
  • “This fundraising marks a pivotal moment for EnginZyme," said Dr. Karim Engelmark Cassimjee, CEO and co-founder of EnginZyme.
  • By replacing traditional fossil-based manufacturing with the patented cell-free technology platform, EnginZyme seeks to accelerate the shift toward the sustainable biomanufacturing of products that modern society relies on.